BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 22467061)

  • 1. Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America.
    Knight G; Earle CC; Cosby R; Coburn N; Youssef Y; Malthaner R; Wong RK;
    Gastric Cancer; 2013 Jan; 16(1):28-40. PubMed ID: 22467061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).
    Leong T; Smithers BM; Michael M; Gebski V; Boussioutas A; Miller D; Simes J; Zalcberg J; Haustermans K; Lordick F; Schuhmacher C; Swallow C; Darling G; Wong R
    BMC Cancer; 2015 Jul; 15():532. PubMed ID: 26194186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
    Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
    Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant and neoadjuvant approaches in gastric cancer.
    Ng K; Meyerhardt JA; Fuchs CS
    Cancer J; 2007; 13(3):168-74. PubMed ID: 17620766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
    Slagter AE; Jansen EPM; van Laarhoven HWM; van Sandick JW; van Grieken NCT; Sikorska K; Cats A; Muller-Timmermans P; Hulshof MCCM; Boot H; Los M; Beerepoot LV; Peters FPJ; Hospers GAP; van Etten B; Hartgrink HH; van Berge Henegouwen MI; Nieuwenhuijzen GAP; van Hillegersberg R; van der Peet DL; Grabsch HI; Verheij M
    BMC Cancer; 2018 Sep; 18(1):877. PubMed ID: 30200910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis.
    Malthaner RA; Wong RK; Rumble RB; Zuraw L;
    BMC Med; 2004 Sep; 2():35. PubMed ID: 15447788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant or adjuvant therapy for resectable gastric cancer? A practice guideline.
    Earle CC; Maroun J; Zuraw L;
    Can J Surg; 2002 Dec; 45(6):438-46. PubMed ID: 12500920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG.
    Leong T; Smithers BM; Haustermans K; Michael M; Gebski V; Miller D; Zalcberg J; Boussioutas A; Findlay M; O'Connell RL; Verghis J; Willis D; Kron T; Crain M; Murray WK; Lordick F; Swallow C; Darling G; Simes J; Wong R
    Ann Surg Oncol; 2017 Aug; 24(8):2252-2258. PubMed ID: 28337660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant and neoadjuvant options in resectable gastric cancer: is there an optimal treatment approach?
    Chen X; Eads JR; Ammori JB; Kumar AM; Biswas T; Dorth JA
    Curr Oncol Rep; 2015 Apr; 17(4):18. PubMed ID: 25708803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What make differences in the outcome of adjuvant treatments for resected gastric cancer?
    Nakajima T; Fujii M
    World J Gastroenterol; 2014 Sep; 20(33):11567-73. PubMed ID: 25206264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS).
    Dikken JL; van Sandick JW; Maurits Swellengrebel HA; Lind PA; Putter H; Jansen EP; Boot H; van Grieken NC; van de Velde CJ; Verheij M; Cats A
    BMC Cancer; 2011 Aug; 11():329. PubMed ID: 21810227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond.
    Choi AH; Kim J; Chao J
    World J Gastroenterol; 2015 Jun; 21(24):7343-8. PubMed ID: 26139980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epirubicin, oxaliplatin, and capectabine is just as "MAGIC"al as epirubicin, cisplatin, and fluorouracil perioperative chemotherapy for resectable locally advanced gastro-oesophageal cancer.
    Sirohi B; Barreto SG; Singh A; Batra S; Mittra A; Rastogia S; Ramadwar M; Shetty N; Goel M; Shrikhande SV
    J Cancer Res Ther; 2014; 10(4):866-70. PubMed ID: 25579520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis.
    Chan KKW; Saluja R; Delos Santos K; Lien K; Shah K; Cramarossa G; Zhu X; Wong RKS
    Int J Cancer; 2018 Jul; 143(2):430-437. PubMed ID: 29441562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic options in gastric cancer: neoadjuvant chemotherapy vs postoperative chemoradiotherapy.
    Jackson C; Mochlinski K; Cunningham D
    Oncology (Williston Park); 2007 Aug; 21(9):1084-7; discussion 1090, 1096-8, 1101. PubMed ID: 17910312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of preoperative chemotherapy with modified FOLFOX6 followed by surgery and postoperative chemoradiation in patients with localized gastric adenocarcinoma.
    Chen SS; Yang XC; Chi F; Yu WZ; Wang ZB; Ning FL; Yu ZS; Hao YZ; Li ML; Wang F; Geng DZ; Liu LH; Dong XJ; Peng XZ; Ji CX
    Oncol Res; 2013; 20(7):327-32. PubMed ID: 23879173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
    Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
    Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
    BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing Therapies in the Perioperative Management of Gastric Cancer.
    Khan U; Shah MA
    Curr Treat Options Oncol; 2019 May; 20(7):57. PubMed ID: 31144054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.